标题
Receptor Tyrosine Kinase-Targeted Cancer Therapy
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 11, Pages 3491
出版商
MDPI AG
发表日期
2018-11-07
DOI
10.3390/ijms19113491
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
- (2018) Jing Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
- (2018) Hiroaki Akamatsu et al. CANCER SCIENCE
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
- (2018) Chiara Tomasello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting EGFR in Lung Cancer: Current Standards and Developments
- (2018) Asunción Díaz-Serrano et al. DRUGS
- miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
- (2018) Cristina Migliore et al. EMBO Molecular Medicine
- Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy
- (2018) Mopa Alina Sooro et al. INTERNATIONAL JOURNAL OF CANCER
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
- (2018) David Cella et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer
- (2018) Jason N Rosenbaum et al. MODERN PATHOLOGY
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Third generation EGFR TKIs: current data and future directions
- (2018) Chee-Seng Tan et al. Molecular Cancer
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
- (2018) Leila Dardaei et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
- (2018) Xiaoyun Lu et al. MEDICINAL RESEARCH REVIEWS
- A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation
- (2018) Jia-Zhou Lin et al. MEDICINE
- Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α)
- (2018) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cabozantinib for the treatment of kidney cancer
- (2017) Ahmed Abdelaziz et al. Expert Review of Anticancer Therapy
- Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
- (2017) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
- (2017) Toshimitsu Yamaoka et al. MOLECULAR CANCER RESEARCH
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
- (2017) Xueli Nan et al. Oncotarget
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- (2017) Maria Apicella et al. Oncotarget
- Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
- (2017) Toshimitsu Yamaoka et al. Jove-Journal of Visualized Experiments
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- (2017) Tristan A. Barnes et al. Frontiers in Oncology
- Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics
- (2017) Spencer B. Mamer et al. Scientific Reports
- Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference
- (2016) Nikolett M. Biel et al. CANCER LETTERS
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
- (2016) Mohamed Alorabi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
- (2016) Yoon Jin Cha et al. Journal of Thoracic Oncology
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
- (2016) Toshimitsu Yamaoka et al. MOLECULAR CANCER THERAPEUTICS
- Afatinib: A Review in Advanced Non-Small Cell Lung Cancer
- (2016) Gillian M. Keating Targeted Oncology
- Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
- (2016) Jenn-Yu Wu et al. OncoTargets and Therapy
- Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- (2016) M. Bahcall et al. Cancer Discovery
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
- (2016) Kenzo Soejima et al. Expert Review of Clinical Pharmacology
- Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
- (2016) Yuli Wang et al. Open Medicine
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
- (2016) Ryohei Katayama et al. EBioMedicine
- Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
- (2016) Irena Ilic et al. PLoS One
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
- (2015) Teresa Helsten et al. CANCER AND METASTASIS REVIEWS
- EGFR T790M resistance mutation in non small-cell lung carcinoma
- (2015) Marc G. Denis et al. CLINICA CHIMICA ACTA
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab
- (2015) Chikako Shimizu et al. Breast Cancer
- FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
- (2015) F. Li et al. Cancer Discovery
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
- (2015) Song Yi Bae et al. Oncotarget
- Experience with erlotinib in the treatment of non-small cell lung cancer
- (2015) Lorenza Landi et al. Therapeutic Advances in Respiratory Disease
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
- (2014) G. V. Scagliotti et al. ANNALS OF ONCOLOGY
- Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
- (2014) Yun Shi et al. BREAST CANCER RESEARCH
- A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
- (2014) N. Elster et al. BREAST CANCER RESEARCH AND TREATMENT
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- (2014) B. Escudier et al. CLINICAL CANCER RESEARCH
- Afatinib for the treatment of advanced non-small-cell lung cancer
- (2014) Carlo Genova et al. EXPERT OPINION ON PHARMACOTHERAPY
- Afatinib and lung cancer
- (2014) Prantesh Jain et al. Expert Review of Anticancer Therapy
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence
- (2014) Valentina Martin et al. Molecular Oncology
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
- (2013) Lise Roca et al. BREAST CANCER RESEARCH AND TREATMENT
- Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
- (2013) Christina Brzezniak et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
- (2013) Hyeong Ryul Kim et al. Molecular Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
- (2013) Zheng Jiang et al. PLoS One
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
- (2012) H. K. Gan et al. CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
- (2012) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
- (2012) Irène Asmane et al. EUROPEAN JOURNAL OF CANCER
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
- (2011) Fausto Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells
- (2011) M. J. Jameson et al. MOLECULAR CANCER THERAPEUTICS
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
- (2011) B N Rexer et al. ONCOGENE
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- The role of the c-Met pathway in lung cancer and the potential for targeted therapy
- (2011) Martin Sattler et al. Therapeutic Advances in Medical Oncology
- EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
- (2011) Kimberly J Gorden et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
- (2010) A Gualberto et al. BRITISH JOURNAL OF CANCER
- Vascular endothelial growth factor receptor-1 in human cancer
- (2010) Jonathan D. Schwartz et al. CANCER
- MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
- (2010) V. Cepero et al. CANCER RESEARCH
- Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
- (2010) Animesh Pardanani et al. CURRENT OPINION IN HEMATOLOGY
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
- (2010) Simona Corso et al. Molecular Cancer
- Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
- (2010) D. B. Ulanet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
- (2009) A. W. Gramza et al. CLINICAL CANCER RESEARCH
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
- (2009) J. Zha et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor
- (2009) K. Sakurama et al. MOLECULAR CANCER THERAPEUTICS
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
- (2008) Narasimhan P. Agaram et al. GENES CHROMOSOMES & CANCER
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression
- (2008) Lei L Chen et al. MODERN PATHOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
- (2008) C. Tarn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search